Neuronal Ceroid Lipofuscinosis Type 6 (CLN6) clinical findings and molecular diagnosis: Costa Rica’s experience

R. Badilla-Porras1, A. Echeverri-McCandless2, J. M. Weimer3, A. Ulate-Campos4, A. Soto-Rodríguez2, A. Gutiérrez-Mata4, L. Hernández-Con4, S. Bogantes-Ledezma4, A. Balmaceda-Meza5, J. Brudvig3 and A. Sanabria-Castro2,6

Abstract

Background: Commonly known as Batten disease, the neuronal ceroid lipofuscinoses (NCLs) are a genetically heterogeneous group of rare pediatric lysosomal storage disorders characterized by the intracellular accumulation of autofluorescent material (known as lipofuscin), progressive neurodegeneration, and neurological symptoms. In 2002, a disease-causing NCL mutation in the CLN6 gene was identified (c.214G > T) in the Costa Rican population, but the frequency of this mutation among local Batten disease patients remains incompletely characterized, as do clinical and demographic attributes for this rare patient population.

Objective: To describe the main sociodemographic and clinical characteristics of patients with a clinical diagnosis for Batten Disease treated at the National Children’s Hospital in Costa Rica and to characterize via molecular testing their causative mutations.

Methods: DNA extracted from buccal swabs was used for CLN6 gene sequencing. Participants’ sociodemographic and clinical characteristics were also obtained from their medical records.

Results: Nine patients with a clinical diagnosis of Batten disease were identified. Genetic sequencing determined the presence of the previously described Costa Rican homozygous mutation in 8 of 9 cases. One patient did not have mutations in the CLN6 gene. In all cases where the Costa Rican CLN6 mutation was present, it was accompanied by a substitution in intron 2. Patients were born in 4 of the 7 Costa Rican provinces, with an average onset of symptoms close to 4 years of age. No parental consanguinity was present in pedigrees. Initial clinical manifestations varied between patients but generally included: gait disturbances, language problems, visual impairment, seizures and psychomotor regression. Cortical and cerebellar atrophy was a constant finding when neuroimaging was performed. Seizure medication was a common element of treatment regimens.

Conclusions: This investigation supports that the previously characterized c.214G > T mutation is the most common causative NCL mutation in the Costa Rican population. This mutation is geographically widespread among Costa Rican NCL patients and yields a clinical presentation similar to that observed for CLN6 NCL patients in other geographies.
Keywords: Neuronal ceroid lipofuscinosis, Batten disease, CNL6, Variant late infantile NCL, vLINCL, Lysosomal storage disease

Background

Neuronal ceroid lipofuscinoses (NCLs) constitute a group of genetic neurodegenerative diseases associated with motor and cognitive regression; progressive cortical, thalamic, and cerebellar atrophy; retinopathy; epilepsy; and a shortened lifespan [1, 2]. NCLs causative mutations have been mapped to at least 13 different genes, which encode a diverse set of lysosomal enzymes, cytosolic chaperones, and transmembrane proteins with roles in secretory and endolysosomal trafficking [3]. More than 70 mutations have been reported in the CLN6 gene, which are responsible for variant late infantile or adult-onset forms (i.e. Kufs Disease Type A) of NCL [4–6]. The CLN6 gene is located on 15q23 and encodes a 311 amino acid transmembrane endoplasmic reticulum protein that functions in the ER to Golgi transfer of lysosomal enzymes [7]. Downstream cellular pathologies ranging from synaptic alterations, glial activation, and autophagy have also hinted at additional cellular roles or, perhaps, specialized roles in neurons and glia [2, 6, 8–12].

The initial clinical manifestations of CLN6 disease generally begin between the ages of 2 and 4 years [13] and are characterized by motor regression, visual loss, the presence of rapid and involuntary muscle movements, and multiple seizures types [14, 15]. In advanced stages, patients commonly develop ataxia, further cognitive and motor deterioration, and finally spastic quadriparesia [16, 17]. Imaging-based studies commonly find cortical and/or subcortical grey matter atrophy [15, 17–19] and, like most other forms of NCL, there are no approved disease-modifying treatments. Clinical treatment is focused on symptom management and includes the management of seizures, sleep alterations, extrapyramidal symptoms, behavioral disturbances, anxiety and psychosis [14]. Slight variations in the clinical course of CLN6 disease have been linked to the causative mutations and the country of origin [20].

Mutations in the CLN6 gene are observed mainly in patients of Portuguese, Indian, Pakistani or Czech descent, but have also been documented in countries such as Costa Rica, Sudan, Turkey and Japan [16, 21–23]. By the end of the 1990s, studies aimed at identifying and analyzing the most common genetic variant in late infantile NCL began in the Costa Rican population [24–26]. From these studies, the causative alteration known as the Costa Rican CLN6 gene mutation was defined [27]. This genetic modification, described in 2002, corresponds to a nonsense change in exon 3 (c.214G>T; p.E72X) introducing a stop codon at amino acid position 72; which results in a premature termination and generates an incomplete and non-functional protein product that is degraded at the level of the endoplasmic reticulum [6, 22]. Other possible disease-related mutations in the CLN6 gene (specifically in exons 4 [c.368G>A] and 7 [c.722T>C]) have also been reported [28]. Currently in Costa Rica, a NCL diagnosis is made by a clinical evaluation of the symptoms and signs recalled during medical history and present during physical examination by a pediatric neurologist.

Here, we aimed to determine the frequency of the c.214G>T CLN6 gene mutation and any other mutations among Costa Rican NCL patients and to describe the main sociodemographic and clinical characteristics in patients diagnosed with NCL in the National Children’s Hospital (HNN), the only pediatric hospital in Costa Rica, and part of the social security system (CCSS).

Methods

After obtaining approval from the Institution’s Scientific Ethics Committee (CEC-CENTRAL-CCSS) and authorization from the Director of Costa Rica’s National Children’s Hospital (HNN), the parents of all patients with a clinical diagnosis of Batten disease currently treated at the HNN Neurology Department were contacted, the study was explained and the investigators invited the parents so their child could participate. Subsequently, an appointment was scheduled in the HNN and, after explaining the study and obtaining informed consent (informed assent was not possible), the investigator collected a buccal swab for each participant. The samples were dissociated from any personal identification and transported in compliance with international regulations to the appointed laboratory. The genetic analysis of the samples was performed by Sanford Research (Sioux Falls, SD; USA) in two independent laboratories where DNA was extracted and next generation sequencing (NGS) for the CLN6 gene was performed for each study subject. Once the genetic results were obtained, the study participant’s parents received the genetic testing results with an explanation as part of their usual clinical visit.

The main sociodemographic and clinical characteristics from the study subjects were examined with a descriptive analysis based on existing medical records. These included: age, sex, place of birth and residence, age of initial symptom onset, age of clinical diagnosis, relevant medical history, main clinical manifestations and
pertinent evaluations previously performed (ophthalmological evaluation, visual evoked potentials, electroretinogram, electroencephalogram, imaging tests including computerized axial tomography or brain magnetic resonance imaging) at diagnosis, in addition to the result of the most recent neurological examination and current treatment.

All study procedures were carried out in accordance with the Declaration of Helsinki, Good Clinical Practice Standards and local Costa Rican regulations.

Results

Nine patients with a previous clinical diagnosis of NCL were identified. The average age of the subjects when the DNA sample was obtained was 9.9 ± 2.7 years (mean ± SD). The initial symptoms appeared at 3.9 ± 0.6 years on average (range 3-5 years) and the typical age at the time of the clinical diagnosis was approximately 7 years (range 3-10 years). Females outnumbered males in a 2:1 ratio. Most patients (77.8%, n = 7) did not report a significant medical history before the onset of symptoms related to the disease.

The Costa Rican mutation (homozygous nonsense variant in exon 3 c.214G>T in the CNL6 gene) was reported in approximately 90% (n = 8) of study participants. In all cases where the Costa Rican CLN6 mutation was present, it was accompanied by a substitution in intron 2 (c.198 + 104T>C, Table 1) as previously described [4, 22].

Most of the patients were born in and currently live in areas distant from San José, Costa Rica’s capital city. There was a fraternal relationship identified between two patients who live in the province of Limón. Nevertheless, there was no evidence suggesting the presence of specific geographic areas with a higher frequency of cases (Fig. 1).

Likewise, no consanguineous relationships were reported between the parents of study participants.

Gait disorders, vision loss and speech disturbances were the most frequent initial manifestations registered in medical records. Patient’s specific neurological signs and symptoms can be observed in Tables 2 and 3. At the time of clinical diagnosis, 77.7% (n = 7) of the cases presented abnormalities in the ophthalmological assessment with 87.5% (n = 7) of study subjects presenting with altered visual potentials when such data were collected. The majority of study participants showed abnormalities in the EEG and neuroimaging tests, in which cortical, subcortical, and cerebellar atrophies were common (Table 2).

The review of subject’s medical records allowed for a qualitative comparison between the initial clinical manifestations and the findings from the most recent neurological examination, showing a substantial deterioration in physical and functional capabilities over the observation period (Table 3). Valproic acid, carbamazepine and clonazepam were the medications mostly prescribed for the treatment of seizures.

In study patient A, genetic sequencing did not identify the Costa Rican mutation to confirm variant late infantile NCL. Full mutation analysis including: CLN1/PPT1, CLN2/TPP1, CLN3, CLN5, CLN6, CLN7, CLN8 and CLN10/CTSD was suggested for this patient. However, currently our Institution does not have the possibility to extend further genetic testing. After receiving the negative results for this patient new tests were performed and no data supporting alterations in metabolic or biochemical parameters was identified. Genetic confirmation of progressive leukoencephalopathy was also recommended. Currently the patient is receiving palliative care.

![Fig. 1 Geographic distribution of cases. Blue pin indicates the patient without the CLN6 Costa Rican mutation](image-url)
| Patient codification | A  | B  | C  | D  | E  | F  | G  | H  | I  |
|----------------------|----|----|----|----|----|----|----|----|----|
| Age                  | 11 | 13 | 13 | 7  | 12 | 6  | 8  | 8  | 11 |
| Sex                  | Male | Female | Female | Male | Female | Female | Female | Male |
| Age of onset         | 4  | ND | 5  | 4  | 3  | 4  | 4  | 4  | 3  |
| Age of diagnosis     | ND | ND | ND | 10 | 6  | 8  | 8  | 8  | 3  |
| Relevant medical history | Severe myopia | Severe TBI/w/neurological sequelae | None | None | None | None | None | None |
| Genetic              | NI | Homozygous | Homozygous | Homozygous | Homozygous | Homozygous | Homozygous | Homozygous |
| Mutation             | E3: NI | E3: c.214 G>T | E3: c.214 G>T | E3: c.214 G>T | E3: c.214 G>T | E3: c.214 G>T | E3: c.214 G>T | E3: c.214 G>T |
| I2: NI               | I2: c.198 +104 T>C | I2: c.198 +104 T>C | I2: c.198 +104 T>C | I2: c.198 +104 T>C | I2: c.198 +104 T>C | I2: c.198 +104 T>C | I2: c.198 +104 T>C |
| E3: NI               | E3: p.E72X | E3: p.E72X | E3: p.E72X | E3: p.E72X | E3: p.E72X | E3: p.E72X | E3: p.E72X |

ND no data, TBI traumatic brain injury, NI not identified
**Table 2** Clinical manifestations and evaluations at diagnosis

| Patient codification | A | B | C | D | E | F | G | H | I |
|----------------------|---|---|---|---|---|---|---|---|---|
| **Main clinical manifestations** | Behavioral and walking disturbances (ataxic) | Personality and behavior disturbances | Behavioral, walking, motor skills, language and sleep alterations | Alterations of motor skills and the ability to walk | Alterations of motor skills and the ability to walk | Alterations of walking ability (recurrent falls) | Visual and walking alterations | Walking and language alterations | Myoclonic seizures | Attentional difficulties | Cognitive decline | Cognitive decline | Cognitive decline |
| **Ophthalmological evaluation (OE)** | Normal | Bull's eye maculopathy, retinal vessels atrophy, retinal pigment epithelium and retinal alteration | Severe macular and retinal pigment epithelium alteration | Bull's eye maculopathy | ON atrophy | Bilateral ONs atrophy | Bilateral ONs atrophy | Retinal atrophy with light discoloration | Retinal pigment epithelium and retinal alterations | Generalized vascular thinning | Generalized vascular thinning, macula with xanthophyll pigment |
| **Visually evoked potentials (VEP)** | Normal | Lack of response | Lack of response | Myelinopathic disorder | Diffuse axonal injury | Axonal disorder in associative areas | Diffuse axonal injury | Axonal disorder in associative areas | ND | ND |
| **ERG** | ND | Impossible to perform | Paroxysmal epileptic foci in left parietotemporal and right frontal lobes | Bursts of bilateral activity 4 Hz frequency during sleep and wakefulness | Disorganized patterns, focal slow right activity with high voltage bursts. Interictal epileptiform discharges | Absence of paroxysmal epileptic foci, slow posterior activity with generalized rapid rhythmic discharges | Absence of paroxysmal epileptic foci, slow posterior activity | Slow and diffuse baseline activity with greater amplitude in the posterior quadrant | Interictal epileptiform discharges |
| **EEG** | Paroxysmal epileptic foci in left parietotemporal and right frontal lobes | ND | Abolished | ND | ND | ND | Abolished | ND |
| **Medical images** | CT: cortical, subcortical and cerebellar atrophy | CT: cortical atrophy and diffuse subcortical atrophy | CT: cortical atrophy and diffuse subcortical atrophy | MRI: Generalized cerebral and cerebellar atrophy | MRI: severe cortical atrophy | MRI: diffuse cerebral and cerebellar atrophy | MRI: diffuse cerebral and cerebellar atrophy | MRI: diffuse cerebral and cerebellar atrophy | MRI: diffuse cerebral and cerebellar atrophy |

*ERG* electroretinogram, *EEG* electroencephalogram, *ND* no data, *ON* optic nerve, *CT* computerized tomography, *MRI* magnetic resonance imaging
| Patient codification | A | B | C | D | E | F | G | H | I |
|----------------------|---|---|---|---|---|---|---|---|---|
| Neurological examination: motor, consciousness level, visual alterations, epilepsy, functional level | Spastic tetraparesis, Somnolence, Complete lack of visual response, bedridden | Spastic tetraparesis, Somnolence, Lack of visual response to light stimulus, pupil deformity | Increased muscle tone in lower limbs, Somnolence, Blindness, Dyspraxia, Wheelchair bound | General hypotonia, Complete lack of visual response, Unstable in sitting position | Trunk ataxia, Axial hypotonia, Limb hypertonia, Lack of visual response, Normal eye contact, Inability to walk | Tone and muscle strength preserved, Alert, Unstable in sitting position | Spastic quadriparesis, Nistagmus, Focal Myoclonus, Bedridden | Lack of visual response, Right clonus, Able to stand in upright position using both upper limbs | Spastic quadriparesis, Myoclonic seizures |
| Other clinical findings | | | | | | | | | |
| Treatment | Valproic acid | Valproic acid | Valproic acid | Valproic acid | Valproic acid | Valproic acid | Valproic acid | Valproic acid | Valproic acid |
| | Carbamazepine | Carbamazepine | Clonazepam | Topiramate | Carbamazepine | Clonazepam | Topiramate | Carbamazepine | Clonazepam |
| | | | | | | | | L-carnitine | |
Discussion

Worldwide, it has been reported that the initial clinical manifestations in CLN6 disease occur between 2 and 4 years of age [13], however in this investigation, the cases analyzed trended towards the older end of this range with regards to symptom onset (3.9 ± 0.6), with a range between 3 and 5 years of age. This may be due to the small number of cases studied, or possibly to certain variations in the clinical course of the disease linked to this causative mutation as has previously been reported for Costa Rican patients [20]. The age of diagnosis in this study was an average of seven years. This could be due in part to the challenges associated with diagnosis of a complex rare disease in a locality with limited utilization of genetic testing. In this patient cohort, females outnumbered males 2:1. This level of sex disparity has not been reported in clinical literature and is likely due to the small sample size. Differences in severity between the sexes have been documented for some forms of NCL, with more aggressive forms commonly reported in female patients, however this was not recapitulated in our study [29, 30].

The genetic alterations identified in the study population, pointedly the Costa Rican mutation and the substitution polymorphism in intron 2, have been previously reported [4, 22]. This substitution polymorphism has also been described in Argentinian populations [4, 28]. In the Costa Rican Batten disease population, the homozygous mutation and the presence of the polymorphism suggest that the polymorphism and the damaging mutation are inherited as a haplotype. Thus, unlike many other NCL mutations, the Costa Rican c.214G>T mutation has been associated with the founder effect [20, 31]. It is important to mention, that despite not having carried out multi-generation genealogical studies, the presence of the specific haplotype in all study samples, the absence of consanguinity registered in medical records and the varied geographical locations where study subjects were born and live, supports this local founder effect for this allele. It has been suggested that this founder effect was introduced in the initial pool of genes from the time of the Spanish and Portuguese colonization. This hypothesis has been mentioned in other medical conditions described in our country such as Wilson’s Disease [32, 33].

The main signs and symptoms observed in study participants generally agree with what has been reported worldwide for CLN6 patients, where visual loss, the presence of rapid and involuntary muscle movements, seizures, ataxia, and mental and motor deterioration are the most frequent findings described [16, 17]. Specifically, the published literature establishes that motor regression constitutes one of the first clinical manifestations [15], an aspect confirmed in our study subjects, where gait disturbances and alterations of motor skills were near constant findings in the initial stages of the disease (Table 2).

Where neuroimaging studies were available, cortical and/or subcortical atrophy were common findings, as has been consistently reported in NCLs [15, 17–19]. Regarding imaging modalities, magnetic resonance imaging (MRI) had limited availability in Costa Rica over the study period; many patient records thus only had computed tomography (CT) scans. Likewise, ERG equipment was not operational for the duration of the study period and ERG data is available for only three patients in the study. In the majority of the analyzed cases, deterioration was reported in both the ophthalmological evaluation and in the visual evoked potentials (defective macular light reflection, optic disc pallor, attenuation of retinal vessels, pigmented retinal changes, macular degeneration and optic atrophy); all of these findings are congruent with what has been described previously in medical literature [34]. These changes can occur even before the onset of vision loss, which was documented in the present investigation. In this study, similar to what has been reported worldwide, substantial disease progression was observed when comparing the initial clinical manifestations reported in medical records with the findings of the most recent neurological examination [35, 36].

Current therapeutic options in this disease include symptom management for: seizures, sleep problems, extrapyramidal symptoms, behavior problems, anxiety and psychosis. Seizures in NCLs are often refractory to treatment and require the prescription of multiple antiseizure medications such as sodium valproate, lamotrigine, topiramate, levetiracetam, carbamazepine, and benzodiazepine derivatives [37, 38]. There were no major differences regarding the main antiseizure medications prescribed when compared to other countries, and possible variations would be due mainly to the availability of the medication in the country and in the social security health care system (CCSS).

Regarding the study participant in whom the c.214G>T Costa Rican mutation was not identified, it is possible that mutations in other NCL genes could be responsible for the symptoms, as has been documented in other Costa Rican patients [20, 22]. It is worth noting that this was the only patient that presented with a normal ophthalmic evaluation and normal visual evoked potential at diagnosis, demonstrative of some disparity in their disease presentation. Additionally, while vast majority of Costa Rican patients with NCL are treated in the HNN, the possibility (although low) of patients in other regional or private healthcare centers cannot be disregarded.
Conclusion
Collectively, this investigation confirms the presence of the c.214G>T Costa Rican mutation in most Costa Rican patients with clinical symptoms of NCL and sustains that the clinical characteristics of these patients are similar to those described in other regions globally.

Abbreviations
CLN6: Neuronal Cereoid Lipofuscinosis Type 6; CCSS: Costa Rica’s Social Security System; NCLs: Neuronal ceroid lipofuscinoses; HNN: Costa Rica’s National Children’s Hospital; DNA: Deoxynucleobase acid; ER: Endoplasmic reticulum; NGS: Next generation sequencing; SD: South Dakota, USA; United States of America; EEG: Electroencephalogram; ERG: Electroretinogram; ND: NO data; ON: Optic nerve; CT: Computerized tomography; VEP: Visually evoked potentials; APRONET: Costa Rica’s Association for Children with Progressive Neurological Diseases.

Acknowledgements
To Mrs. Yamileth Chaves-Soto, president of Costa Rica’s Association for Children with Progressive Neurological Diseases (APRONET), for her vision and determination in ensuring that this study could be carried out and who also collaborated with the logistical aspects for study participants and their relatives. To Mr. Pablo Solís-Quesada for his collaboration in this study and Sebastián Rojas-Chaves MD for his participation in graphic design.

Authors’ contributions
ASC, RBP and AEM contributed to the design and implementation of the research, to the analysis of the results and to the writing of the manuscript. AUC, AGMI, LHC and SBL were the head doctors of the patients in the study, they contribute with the data collection and review the written manuscript. JW did the genetic sequencing of the patients and helped with the writing of this article. ABM contributed with the extensive bibliographic search and supported the writing of the manuscript. JB participated in the review, writing and as a consultant for clinical insight of the disease. ASR was part of the data collection team and writing, contributed to the data analysis and the design of the figures and graphics. All authors read and approved the final manuscript.

Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Availability of data and materials
The datasets generated and/or analyzed during the current study are not publicly available due to internal policies of the CCSS that prohibited the publication of any patient’s information in any website outside of its network, but are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
After obtaining approval from the Institution’s Scientific Ethics Committee (ICC-CENTRAL-CCSS) and authorization from the Director of Costa Rica’s National Children’s Hospital (HNN), the parents of all patients with a clinical diagnosis of Batten disease currently treated at the HNN Neurology Department were contacted, the study was explained, and the investigators invited the parents so their child could participate. All parents agreed and signed an informed consent form so the patient could participate.

Consent for publication:
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Clinical Genetic and Metabolism Department, National Children’s Hospital, CCSS, San José, Costa Rica. 2 Research Unit, Hospital San Juan de Dios, CCSS, San José, Costa Rica. 3 Pediatrics and Rare Diseases Group, Sanford Research, Sioux Falls, SD, USA. 4 Neurology Department, National Children’s Hospital, CCSS, San José, Costa Rica. 5 CENDEISS, CCSS, San José, Costa Rica. 6 Pharmacy Department, Pharmacy School, Universidad de Costa Rica, San José, Costa Rica.

Received: 30 August 2021 Accepted: 19 December 2021
Published online: 10 January 2022

References
1. Warrier V, Vieira M, Mole SE. Genetic basis and phenotypic correlations of the neuronal ceroid lipofuscinoses. Biochim Biophys Acta Mol Basis Dis. 2013;1832(11):1827–30.
2. Nelvagah L, Lange J, Takahashi K, Tarzuryuk-Wells M, Cooper J. Pathomechanisms in the neuronal ceroid lipofuscinoses. Biochim Biophys Acta Mol Basis Dis. 2019;30:165570.
3. Johnson T, Cain J, White K, Ramírez-Monteleaegre D, Pearce D, Wein J. Therapeutic landscape for Batten disease: current treatments and future prospects. Nat Rev Neurol. 2019;15(3):161–78.
4. Kousi M, Lehesjoki A, Mole S. Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses. Hum Mutat. 2012;33(1):42–63.
5. Mole S. Neuronal ceroid lipofuscinoses (NCL): Eur J Paediatr Neurol. 2006;10(6):265–7.
6. Butz E, Chandrichud U, Mole S, Cotman S. Moving towards a new era of genomics in the neuronal ceroid lipofuscinoses. Biochim Biophys Acta Mol Basis Dis. 2019;30:165571.
7. Bajaj L, Sharma J, di Ronza A, Zhang P, Eblimit A, Pal R, et al. A CLN6-CLN8 complex recruits lysosomal enzymes at the ER for Golgi transfer. J Cell Investig. 2020;130(8):11418–32.
8. Cárcel-Trullols J, Kovács AD, Pearce DA. Cell biology of the NCL proteins: what they do and don’t do. Biochim Biophys Acta Mol Basis Dis. 2015;1852(10):2242–55.
9. von Eisenhart-Rothe P, Grubman A, Greferath U, Fothergill L, Jobling A, Phipps J, et al. Failure of autophagy-lysosomal pathways in rod photoreceptors causes the early retinal degeneration phenotype observed in Cln6null mice. Invest Ophtalmol Vis Sci. 2018;59(12):5082–97.
10. Heine C, Koch B, Storch S, Kohlchüchter A, Palmer D, Baulake T. Defective endoplasmic reticulum-resident membrane protein CLN6 affects lysosomal degradation of endocytosed arylsulfatase. A J Biol Chem. 2004;279(21):22347–52.
11. Cain J, Likhite S, White K, Timm D, Davis S, Johnson T, et al. Gene therapy corrects brain and behavioral pathologies in CLN6-Batten disease. Mol Ther. 2019;27(10):1836–47.
12. Morgan J, Magee H, Wong A, Nelson T, Koch B, Cooper J, et al. A murine model of variant late infantile ceroid lipofuscinosis recapitulates behavioral and pathological phenotypes of human disease. PLoS ONE. 2013;8(11):e78694.
13. Mole SE, Cotman SL. Genetics of the neuronal ceroid lipofuscinoses (Batten disease). Biochim Biophys Acta Mol Basis Dis. 2015;1852(10):2237–41.
14. Nita DA, Mole SE, Minassian BA. Neuronal ceroid lipofuscinoses. Epileptic Disord. 2016;18(52):73–88.
15. Cannelli N, Garavaglia B, Simonati A, Aiello C, Barzaghi C, Pezzini F, et al. Variant late infantile ceroid lipofuscinoses associated with novel mutations in CLN6. Biochem Biophys Res Commun. 2009;379(4):892–7.
16. Nafi O, Ramadan B, Riess O, Buchert R, Froukh T. Two cases of variant late infantile ceroid lipofuscinosis in Jordan. World J Clin cases. 2019;7(2):203–8.
17. Peña J, Montiel-Nava C, Delgado W, Hernández M, Cardozo J, Mora E, et al. Characterization of neuronal ceroid lipofuscinosis in Venezuelan children. Rev Neurol. 2004;38(1):42–8.
18. Petersen B, Handwerker M, Huppertz H. Neuroradiological findings in classical late infantile neuronal ceroid-lipofuscinosis. Pediatr Neurol. 1996;15(4):344–7.
19. Kohan R, Pesaoa F, Guelbert N, Pons P, Oller-Ramírez A, Rautenberg G, et al. The neuronal ceroid lipofuscinoses program: A translational research experience in Argentina. Biochim Biophys Acta. 2015;1852(10 Pt B):2301–11.
20. Sharp J, Wheeler R, Parker K, Gardiner R, Williams R, Mole S. Spectrum of CLN6 mutations in variant late infantile neuronal ceroid lipofuscinosis. Hum Mutat. 2003;22(1):35–42.
21. Markham A. Cerliponase Alfa: first global approval. Drugs. 2017;77(1):1247–9.
22. Wheeler R, Sharp J, Schultz R, Joslin J, Williams R, Mole S. The gene mutated in variant late‑infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice encodes a novel predicted transmembrane protein. Am J Hum Genet. 2002;70(2):537–42.
23. Matsumoto A, Nagashima M, Iwama K, Mizuguchi T, Makino S, Ikeda T, et al. Rapid progression of a walking disability in a 5‑year‑old boy with a CLN6 mutation. Brain Dev. 2019;41(8):726–30.
24. Gao H, Boustany R‑MN, Espinola JA, Cotman SL, Srinidhi L, Antonelli KA, et al. Mutations in a Novel CLN6‑Encoded Transmembrane Protein Cause Variant Neuronal Ceroid Lipofuscinosis in Man and Mouse. Am J Hum Genet. 2002;70(2):324–35.
25. Auger KJ, Ajene A, Lerner T. Progress toward the Cloning of CLN6, the gene underlying a variant LINCL. Mol Genet Metab. 1999;66(4):332–6.
26. Haines JL, Boustany RM, Alroy J, Auger KJ, Shook KS, Terverdow H, et al. Chromosomal localization of two genes underlying late‑infantile neuronal ceroid lipofuscinosis. Neurogenetics. 1998;1(3):217–22.
27. Boustany R‑M. Neurodystrophies and lipodosis. In: Moser H, editor. Handbook of clinical neurology, vol. 22. Amsterdam: Elsevier; 1997. p. 671–700.
28. Mole S. UCL NCL Mutation and, Patient Database [Internet]. 2019 [cited 2019 Nov 15]. Available from: https://www.ucl.ac.uk/ncl-disease/mutation-and-patient-database.
29. Cialone J, Adams H, Augustine E, Marshall F, Kwon J, Newhouse N, et al. Females experience a more severe disease course in Batten disease. J Inherit Metab Dis. 2012;35(5):549–55.
30. Otstgaard J. Juvenile neuronal ceroid lipofuscinosis (Batten disease): current insights. Degener Neurol Neuromuscul Dis. 2016;6:73–83.
31. Carvajal‑Carmona L, Ophoff R, Service S, Hartliala J, Molina J, Leon P, et al. Genetic demography of Antioquia (Colombia) and the Central Valley of Costa Rica. Hum Genet. 2003;112(5–6):534–41.
32. Herra SA, Hevia FJ, Vargas M, Schosinsky K. Fullminant Wilson’s disease in Costa Rica. Clinico‑pathological study of 7 cases. G E N. 1999;44(1):9–14.
33. Loudianos G, Desi V, Lolicu M, Angius A, Figus A, Lilliu F, et al. Molecular characterization of Wilson disease in the Sardinian population—evidence of a founder effect. Hum Mutat. 1999;14(4):294–303.
34. Verma R, Raut T, Tiwari N, Mahlotha K, Hussain N, Mahlotha H. Late infantile neuronal ceroid lipofuscinosis: a case report with review of literature. Ann Indian Acad Neurol. 2013;16(2):282–5.
35. Simonati A, Williams R, Nardocci N, Laine M, Battini R, Schulz A, et al. Phenotype and natural history of variant late infantile ceroid‑lipofuscinosis S. Dev Med Child Neurol. 2017;59(8):815–21.
36. Steinfeld R, Heim P, von Gregory H, Meyer K, Ulrich K, Goebel HH, et al. Late infantile neuronal ceroid lipofuscinosis: quantative description of the clinical course in patients withCLN2 mutations. Am J Med Genet. 2002;112(4):347–54.
37. Mole S, Halfa M. The Neuronal Ceroid‑Lipofuscinoses (Batten Disease). In: Roger N, Rosenberg R, JM P, editors. Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease. San Diego, California; 2015. p. 793–808.
38. Al‑Muhaizea M, Al‑Hassnan Z, Chedrawi A. Variant late infantile neuronal ceroid lipofuscinosis (CLN6 gene) in Saudi Arabia. Pediatr Neurol. 2009;41(1):74–6.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.